Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms
Study Details
Study Description
Brief Summary
This pilot study will assess feasibility and to obtain initial estimates of efficacy of Sleep Activity and Task Effectiveness (SAFTE) model, which can accurately estimate the impact of scheduling factors and sleep history on both safety and productivity. The SAFTE model will be used to asses cancer-related fatigue and study potential associations of change in sleep patterns to tumor recurrence in patients with high grade glioma. Data will be collected using the Readiband™ Sleep Tracker (https://www.fatiguescience.com/sleep-science-technology/). The Readiband device captures high-resolution sleep data, validated against the clinical gold standard of polysomnography with 92% accuracy. Sleep data is transmitted to the cloud automatically for SAFTE Fatigue Model analysis. We will correlate clinical progression data obtained from the patient's electronic medical record with SAFTE data.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Readiband Sleep Tracking - Patient This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. |
Device: Readiband Sleep Tracking
Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
|
| Readiband Sleep Tracking - Control Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes. |
Device: Readiband Sleep Tracking
Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
|
Outcome Measures
Primary Outcome Measures
- Correlation between sleep patterns and disease progression/recurrence [Participant enrollment to 12 months (or until tumor progression)]
An estimate of correlation between sleep patterns in the brain tumor patient population and disease progression or recurrence compared to those of the general population.
Secondary Outcome Measures
- Correlation between SAFTE fatigue predictions and self-reported fatigue levels [Participant enrollment to 12 months (or until tumor progression)]
An estimate of correlation between SAFTE fatigue predictions and self-reported fatigue levels in patients with GBM
- Sleep pattern differences between healthy controls and brain tumor patients [Participant enrollment to 12 months (or until tumor progression)]
Comparison of differences in sleep patterns in brain tumor patients to those of the general population.
- Correlation between fatigue and sleep patterns and treatment tolerance/success [Participant enrollment to 12 months (or until tumor progression)]
An estimate of correlation between fatigue and sleep patterns and treatment tolerance/success, as determined by MRI imaging and RANO criteria.
- Change in Sleep, Activity, Fatigue, and Task Effectiveness (SAFTE) score [Participant enrollment to 12 months (or until tumor progression)]
Eligibility Criteria
Criteria
Inclusion Criteria
-
Patients aged between 22 and 70. ii. Patients must have a histologic diagnosis of primary Grade IV glioma. iii. Patients must have received maximal debulking surgery and radiotherapy concomitant with Temozolomide (≥ 75% of their recommended temozolomide dosage is required).
-
Patients with KPS ≥70. v. Life expectancy at least 3 months. vi. Patients must have signed informed consent for study participation. vii. Patients should be English speakers.
Exclusion Criteria
-
Patients enrolled in active clinical treatment trials for primary Grade IV glioma.
-
Patients with progressive disease after completion of radiotherapy concomitant with Temozolomide as per RANO criteria. Suspected pseudoprogression should be confirmed by additional imaging studies ordered as part of standard care.
-
Patients with known other active malignancy diagnosed in the past 3 years (except for in situ malignancies).
-
Patients who are pregnant or trying to get pregnant. v. Patients unable to wear the ReadiBand device continuously during study duration.
-
Patients with infra-tentorial tumors. vii. Patients with known psychiatric concerns.
-
Significant co-morbidities at baseline which would prevent maintenance Temozolomide treatment:
-
Thrombocytopenia (platelet count < 100 x 103/μL)
-
Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
-
CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
-
Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
-
Total bilirubin > upper limit of normal, if clinically significant
-
Significant renal impairment (serum creatinine > 1.7 mg/dL)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Abbott Northwestern Hospital | Minneapolis | Minnesota | United States | 55407 |
Sponsors and Collaborators
- Allina Health System
Investigators
- Principal Investigator: John Trusheim, MD, Allina Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NSJT-1701